SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer's lab
Whatever Roche $ROG learned about SQZ over the last 33 months clearly only whetted their appetite for much, much more.
This morning SQZ is unveiling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
